Long-term efficacy and safety of two doses of Norditropin ® (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients.

MLA

Horikawa, Reiko, et al. “Long-Term Efficacy and Safety of Two Doses of Norditropin ® (Somatropin) in Noonan Syndrome: A 4-Year Randomized, Double-Blind, Multicenter Trial in Japanese Patients.” Endocrine Journal, vol. 67, no. 8, Aug. 2020, pp. 803–18. EBSCOhost, https://doi.org/10.1507/endocrj.EJ19-0371.

APA

Horikawa, R., Ogata, T., Matsubara, Y., Yokoya, S., Ogawa, Y., Nishijima, K., Endo, T., & Ozono, K. (2020). Long-term efficacy and safety of two doses of Norditropin ® (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients. Endocrine Journal, 67(8), 803–818. https://doi.org/10.1507/endocrj.EJ19-0371

Chicago

Horikawa, Reiko, Tsutomu Ogata, Yoichi Matsubara, Susumu Yokoya, Yoshihisa Ogawa, Keiji Nishijima, Takaaki Endo, and Keiichi Ozono. 2020. “Long-Term Efficacy and Safety of Two Doses of Norditropin ® (Somatropin) in Noonan Syndrome: A 4-Year Randomized, Double-Blind, Multicenter Trial in Japanese Patients.” Endocrine Journal 67 (8): 803–18. doi:10.1507/endocrj.EJ19-0371.